It will explore how these molecules drive tumor growth, and suggests that targeting C3a and C5a alongside standard therapies like chemotherapy, radiotherapy, and immune-checkpoint inhibitors could enhance cancer treatment outcomes [15,16]. This evidence concerns the gene C5AR1 and cancer.